http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1741431-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae0adfeb8930dcef5c2ca2469e3e5879
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4965
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4965
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
filingDate 2005-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5602fc5768e8d06eb045e77728dcd72a
publicationDate 2007-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-1741431-A1
titleOfInvention The combination for treating hyperlipemia
abstract The present invention provides a composition for treating hyperlipemia, which comprises the first active component acipimox, and the second active component atorvastatin, or the pharmaceutically acceptable salt, ester or solvate thereof. Weight ratio of the first to the second active component is (10-80):1. The composition is in the form of tablets, capsules, granules, pills or dropping pills. The combination of acipimox and atorvastatin is shown to have remarkably synergistic effect in decreasing serum total cholesterol, serum triglyceride and low density lipoprotein-cholesterol. Furthermore, in comparison with the combination of acipimox and pravastatin or the combination of acipimox and lorvastatin, the combination of acipimox and atorvastatin is shown to have more remarkable lipid decreasing effect, and have more advantageous effect of increasing high density lipoprotein-cholesterol.
priorityDate 2004-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4002750-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0128999-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02058685-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003162827-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129317935
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11865464
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID938
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394916
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226434332
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID55303094
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID166304
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136080371
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127744388
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129205760
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127688846
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129742546
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45051774
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6251
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID53232
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11177
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54454
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID586
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87076368
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395935
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12206
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID445127
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395936
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9851656
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393819
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5917
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395910
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393829
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60822
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12040205
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127684899
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226547528
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395911
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393830
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128704946
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54687
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127754342
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60823
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID114873
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394161
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226432772
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23623894
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129200050
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393956
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395390
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID62726
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID91525289
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395391
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226415785
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394009
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3036305
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID229045510
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394915
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID248698204
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5362585
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128898221
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5310993

Total number of triples: 80.